JY
LCTX icon

Jeff Yass’s Lineage Cell Therapeutics LCTX Stock Holding History

Jeff Yass’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.8K Sell
62,427
-1,242,258
-95% -$1.72M ﹤0.01% 12622
2026
Q1 		$2.06M Buy
1,304,685
+598,270
+85% +$1.01M ﹤0.01% 6121
2025
Q4 		$1.18M Buy
706,415
+521,415
+282% +$902K ﹤0.01% 6817
2025
Q3 		$313K Sell
185,000
-362,242
-66% -$429K ﹤0.01% 10013
2025
Q2 		$497K Buy
547,242
+311,133
+132% +$185K ﹤0.01% 9190
2025
Q1 		$107K Buy
236,109
+172,795
+273% +$101K ﹤0.01% 11496
2024
Q4 		$31.8K Buy
63,314
+52,318
+476% +$38.4K ﹤0.01% 11826
2024
Q3 		$9.96K Sell
10,996
-60,326
-85% -$55.9K ﹤0.01% 11721
2024
Q2 		$71.1K Buy
71,322
+36,017
+102% +$39.8K ﹤0.01% 11237
2024
Q1 		$52.3K Sell
35,305
-25,774
-42% -$29.2K ﹤0.01% 11549
2023
Q4 		$66.6K Buy
+61,079
New +$66.9K ﹤0.01% 11580
2023
Q3 		– Sell
-41,181
Closed -$56K – 12527
2023
Q2 		$58.1K Sell
41,181
-775,206
-95% -$1.07M ﹤0.01% 11274
2023
Q1 		$1.22M Buy
816,387
+642,768
+370% +$897K ﹤0.01% 6285
2022
Q4 		$203K Buy
+173,619
New +$219K ﹤0.01% 10088
2022
Q1 		– Sell
-66,430
Closed -$103K – 13544
2021
Q4 		$163K Sell
66,430
-53,271
-45% -$125K ﹤0.01% 11695
2021
Q3 		$302K Buy
119,701
+46,982
+65% +$121K ﹤0.01% 10589
2021
Q2 		$207K Sell
72,719
-927,463
-93% -$2.4M ﹤0.01% 11532
2021
Q1 		$2.35M Buy
1,000,182
+863,839
+634% +$2.07M ﹤0.01% 5530
2020
Q4 		$240K Buy
+136,343
New +$191K ﹤0.01% 9734
2020
Q2 		– Sell
-29,981
Closed -$26.4K – 10558
2020
Q1 		$25K Sell
29,981
-29,310
-49% -$29.2K ﹤0.01% 9885
2019
Q4 		$53K Sell
59,291
-7,029
-11% -$5.86K ﹤0.01% 9328
2019
Q3 		$65K Sell
66,320
-43,670
-40% -$45.2K ﹤0.01% 9708
2019
Q2 		$121K Buy
109,990
+37,370
+51% +$43.1K ﹤0.01% 9514
2019
Q1 		$95K Buy
+72,620
New +$90.3K ﹤0.01% 8269
2018
Q3 		– Sell
-34,690
Closed -$63K – 9779
2018
Q2 		$63K Buy
34,690
+3,944
+13% +$7.94K ﹤0.01% 9211
2018
Q1 		$72K Sell
30,746
-67,670
-69% -$159K ﹤0.01% 8833
2017
Q4 		$185K Buy
+98,416
New +$215K ﹤0.01% 8339
2017
Q3 		– Sell
-41,960
Closed -$104K – 9256
2017
Q2 		$116K Sell
41,960
-10,881
-21% -$30.4K ﹤0.01% 8618
2017
Q1 		$159K Sell
52,841
-94,211
-64% -$268K ﹤0.01% 8158
2016
Q4 		$464K Buy
147,052
+119,051
+425% +$366K ﹤0.01% 7157
2016
Q3 		$96K Buy
28,001
+10,488
+60% +$29K ﹤0.01% 7958
2016
Q2 		$40K Buy
+17,513
New +$42.9K ﹤0.01% 8281
2015
Q4 		– Sell
-64,116
Closed -$192K – 9705
2015
Q3 		$155K Buy
64,116
+27,900
+77% +$72.2K ﹤0.01% 8898
2015
Q2 		$106K Sell
36,216
-16,840
-32% -$65.3K ﹤0.01% 9643
2015
Q1 		$213K Buy
53,056
+21,011
+66% +$72.7K ﹤0.01% 8540
2014
Q4 		$96K Sell
32,045
-10,793
-25% -$29.2K ﹤0.01% 9202
2014
Q3 		$109K Sell
42,838
-14,526
-25% -$35K ﹤0.01% 9044
2014
Q2 		$141K Buy
+57,364
New +$130K ﹤0.01% 9277
2014
Q1 		– Sell
-14,733
Closed -$43.4K – 9177
2013
Q4 		$43K Buy
+14,733
New +$44.5K ﹤0.01% 8827
2013
Q3 		– Sell
-44,498
Closed -$141K – 8597
2013
Q2 		$142K Buy
+44,498
New +$143K ﹤0.01% 7658

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return

Jeff Yass's LCTX Position: Q2 2026 in Review

Jeff Yass reduced its Lineage Cell Therapeutics (LCTX) stake by 95% in Q2 2026, selling an estimated $1.72M and leaving 62,427 shares worth $81.8K. The position accounts for ﹤0.01% of the portfolio, ranked #12622.

Jeff Yass first reported a position in LCTX in Q2 2013 and has held it in 40 quarters since. The position peaked at $2.35M in Q1 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Jeff Yass held 62,427 shares of Lineage Cell Therapeutics worth $81.8K as of Q2 2026.
  • Jeff Yass sold 1,242,258 Lineage Cell Therapeutics shares in Q2 2026, an estimated $1.72M.
  • Lineage Cell Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12622 holding.
  • Jeff Yass first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • Jeff Yass's Lineage Cell Therapeutics position peaked at $2.35M in Q1 2021.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.